绿叶制药(02186.HK):地舒单抗注射液(LY01011)启动临床III期试验
格隆汇 12 月 15日丨绿叶制药(02186.HK))宣布,集团子公司山东博安生物技术有限公司("博安生物")产品地舒单抗注射液(LY 01011)于中国启动临床比对试验(III期)。
LY 01011为地舒单抗注射液(Xgeva®生物类似药),用于预防多发性骨髓瘤和实体瘤骨转移患者骨相关事件;用於治疗不可手术切除或者手术切除可能导致严重功能障碍的骨巨细胞瘤,包括成人和骨骼发育成熟的青少年患者;及用於治疗双膦酸盐难治性恶性肿瘤引发的高钙血症(HCM)。
根据公开的财务报告,Xgeva®于2019年的全球销售额为19.4亿美元,同比增长率为8.3%,并於2019年5月获得中国上市批准。集团的地舒单抗注射液亦已在美国和欧洲开始临床试验。
除地舒单抗注射液外,博安生物凭藉高效创新的内部能力已开发出10余个拥有国际知识产权保护的创新抗体和8个生物类似药。生物类似药方面,LY 01008(Avastin之生物类似药)已申报中国上市申请;LY 06006(Prolia之生物类似药)处于中国III期临床及欧美I期临床;LY 09004(Eylea之生物类似药)处于中国III期临床。此外,一个创新抗体项目已进入中国I期临床。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.